WuXi AppTec looks to unload its Philadelphia manufacturing sites and WuXi Biologics slows its rapid expansion in the U.S. as ...

WuXi is considering the sale of some US and European operations to mitigate the impact of upcoming restrictions.

As the BIOSECURE Act works its way through the U.S. legislative branch, two companies named in the bill are reportedly ...

Ahead of the BIOSECURE Act, WuXi AppTec is in talks to sell its Philadelphia-based cell and gene therapy unit, and WuXi ...

The current status of the Biosecure Act is that it was passed ​ by the US House of Representatives on Sep 9, with a vote of ...

Drugmakers have been targeted on national security grounds and could lose customers if Congress passes Biosecure Act ...

WuXi Biologics is expected to report a more modest pace of top-line expansion and lower profit margins in fiscal 2024. See ...

The BIOSECURE Act passed the House of Representatives on September 9, 2024, with a bipartisan vote of 306–81. It has now moved to the Senate, ...

After experiencing a series of ups and downs in recent years, the biopharma contracting business is gearing up for a rebound ...